12 November 2020                
EMA/599401/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Trimbow 
beclometasone / formoterol / glycopyrronium bromide 
On 12 November 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Trimbow. The marketing authorisation holder for this medicinal product is Chiesi Farmaceutici S.p.A. 
The CHMP adopted a new pharmaceutical strength (172 micrograms/5 micrograms/9 micrograms) with a 
new indication as follows: 
Asthma 
Maintenance treatment of asthma, in adults not adequately controlled with a 
maintenance combination of a long-acting beta2-agonist and high dose of inhaled 
corticosteroid, and who experienced one or more asthma exacerbations in the previous 
year. 
The CHMP also adopted this indication for the already authorised strength (87 micrograms/5 
micrograms/9 micrograms) as follows:2 
COPD 
Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary 
disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and 
a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting 
muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see 
section 5.1). 
Asthma 
Maintenance treatment of asthma, in adults not adequately controlled with a 
maintenance combination of a long-acting beta2-agonist and medium dose of inhaled 
corticosteroid, and who experienced one or more asthma exacerbations in the previous 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
year. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Trimbow  
EMA/599401/2020 
Page 2/2 
 
 
 
 
